Genazzani Alessandro D, Lanzoni Chiara, Ricchieri Federica, Jasonni Valerio M
Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Italy.
Gynecol Endocrinol. 2008 Mar;24(3):139-44. doi: 10.1080/09513590801893232.
To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of PCOS patients.
Controlled clinical study.
PCOS patients in a clinical research environment.
20 overweight PCOS patients were enrolled after informed consent.
All patients underwent hormonal evaluations and an oral glucose tollerance test (OGTT) before and after 12 weeks of therapy (Group A (n = 10): myo-inositol 2 gr. plus folic acid 200 mug every day; Group B (n = 10): folic acid 200 mug every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
评估给予多囊卵巢综合征（PCOS）患者肌醇（MYO）对激素参数的影响。
对照临床研究。
临床研究环境中的PCOS患者。
20名超重的PCOS患者在签署知情同意书后入组。
所有患者在治疗12周前后均接受激素评估和口服葡萄糖耐量试验（OGTT）（A组（n = 10）：每天服用2克肌醇加200微克叶酸；B组（n = 10）：每天服用200微克叶酸）。还进行了超声检查和费里曼-盖尔维评分。
血浆促黄体生成素（LH）、促卵泡生成素（FSH）、泌乳素（PRL）、雌二醇（E2）、17α-羟孕酮（17OHP）、雄烯二酮（A）、睾酮（T）、葡萄糖、胰岛素、C肽浓度、体重指数（BMI）、稳态模型评估胰岛素抵抗指数（HOMA指数）和葡萄糖与胰岛素比值。
服用MYO 12周后，血浆LH、PRL、T、胰岛素水平及LH/FSH显著降低。以葡萄糖与胰岛素比值和HOMA指数表示的胰岛素敏感性在治疗12周后显著改善。所有闭经和月经过少的受试者月经周期恢复正常。服用叶酸的患者未出现变化。
给予肌醇可改善PCOS患者的生殖轴功能，降低影响LH分泌的高胰岛素血症状态。
